Am J Psychiatry. 2014 Oct;171(10):1067-73. doi: 10.1176/appi.ajp.2014.13111501.
This study examined the risk of antidepressant-induced manic switch in patients with bipolar disorder treated either with antidepressant monotherapy or with an antidepressant in conjunction with a mood stabilizer.
Using Swedish national registries, the authors identified 3,240 patients with bipolar disorder who started treatment with an antidepressant and had no antidepressant treatment during the previous year. Patients were categorized into those receiving antidepressant monotherapy and those receiving an antidepressant plus a mood stabilizer. A within-individual design was used to control for confounding by disorder severity, genetic makeup, and early environmental factors. Cox regression analyses conditioned on individual were used to compare the rate of mania 0-3 months and 3-9 months after the start of antidepressant treatment with a preceding non-treatment period.
Nearly 35% of the patients were treated with antidepressant monotherapy. The increased risk of treatment-emergent mania was confined to patients on antidepressant monotherapy (hazard ratio=2.83, 95% CI=1.12, 7.19). Among patients treated with a concurrent mood stabilizer, no acute change in risk of mania was observed during the 3 months after the start of antidepressant treatment (hazard ratio=0.79, 95% CI=0.54, 1.15), and a decreased risk was observed during the period 3-9 months after treatment initiation (hazard ratio=0.63, 95% CI=0.42, 0.93).
In this national registry study, antidepressant monotherapy was associated with an increased risk of mania. However, no risk of mania was seen in patients receiving an antidepressant while treated with a mood stabilizer. The results highlight the importance of avoiding antidepressant monotherapy in the treatment of bipolar disorder.
本研究旨在探讨在接受抗抑郁药单药治疗或抗抑郁药联合心境稳定剂治疗的双相障碍患者中,抗抑郁药诱发躁狂发作的风险。
利用瑞典全国登记处,作者确定了 3240 名开始接受抗抑郁药治疗且在前一年无抗抑郁药治疗的双相障碍患者。患者分为接受抗抑郁药单药治疗和接受抗抑郁药加心境稳定剂治疗的两组。采用个体内设计控制疾病严重程度、遗传构成和早期环境因素的混杂。使用条件 Cox 回归分析比较抗抑郁药治疗开始后 0-3 个月和 3-9 个月与治疗前非治疗期的躁狂发生率。
近 35%的患者接受抗抑郁药单药治疗。抗抑郁药单药治疗组发生治疗后躁狂的风险增加(危险比=2.83,95%CI=1.12,7.19)。在同时使用心境稳定剂的患者中,抗抑郁药治疗开始后 3 个月内观察到躁狂风险无急性变化(危险比=0.79,95%CI=0.54,1.15),治疗开始后 3-9 个月风险降低(危险比=0.63,95%CI=0.42,0.93)。
在这项全国登记研究中,抗抑郁药单药治疗与躁狂风险增加相关。然而,在接受心境稳定剂治疗的同时接受抗抑郁药治疗的患者中,并未观察到躁狂风险。这些结果强调了在治疗双相障碍时避免抗抑郁药单药治疗的重要性。